期刊
CELL REPORTS MEDICINE
卷 2, 期 8, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.xcrm.2021.100353
关键词
-
资金
- National Natural Science Foundation of China [31930035, 91942311, 81971487]
- Shanghai Science and Technology Commission [20JC1410100]
Innate lymphoid cells (ILCs) are tissue-resident lymphocytes without antigen-specific receptors, and their roles in cancer immunity and immunotherapy are still unclear. Studies have identified tumor-specific ILC subsets in colorectal cancer (CRC) patients, with SLAMF1 potentially serving as an anti-tumor biomarker.
Innate lymphoid cells (ILCs) are tissue-resident lymphocytes differing from conventional T lymphocytes in having no antigen-specific receptors. ILCs include natural killer (NK) cells, helper-like ILC1s, ILC2s, and ILC3s, and lymphoid tissue-inducer (LTi) cells. Tumor ILCs are frequently found in various cancers, but their roles in cancer immunity and immunotherapy remain largely unclear. We report here the single-cell characterization of blood and gut helper-like ILC subsets in healthy conditions and in colorectal cancer (CRC). The healthy gut contains ILC1s, ILC3s, and ILC3/NKs, but no ILC2s. Additional tumor-specific ILC1 -like and ILC2 subsets were identified in CRC patients. Signaling lymphocytic activation molecule family member 1 (SLAMF1) was found to be selectively expressed on tumor-specific ILCs, and higher levels of SLAMF1(+) ILCs were observed in the blood of CRC patients. The SLAMF1-high group of CRC patients had a significantly higher survival rate than the SLAMF1 -low group, suggesting that SLAMF1 is an anti-tumor biomarker in CRC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据